Denaverine
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | intramuscular injection, suppositories |
| ATCvet code | QG02CX90 (WHO) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability |
8% (suppositories), 37% (oral solution) |
| Metabolism | mainly hepatic, at least 11 metabolites |
| Biological half-life | 34 hours |
| Identifiers | |
| |
| CAS Number |
3579-62-2  3321-06-0 (hydrochloride) |
| PubChem (CID) | 71130 |
| ChemSpider |
64278  |
| UNII |
O14NF38MTL |
| KEGG |
D07787 |
| ChEMBL |
CHEMBL1614656 |
| Chemical and physical data | |
| Formula | C24H33NO3 |
| Molar mass | 383.52 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
Denaverine is an antispasmodic drug. It was developed in Germany and patented in 1974. Denaverine hydrochloride is used in veterinary medicine under the trade name Sensiblex as a muscle relaxant for the myometrium of cows and dogs during childbirth.[1] Under the trade name Spasmalgan, it has also been used in humans for the treatment of urogenital and gastrointestinal spasms.[2]
Mechanism of action
Denaverine, like papaverine, acts as a phosphodiesterase inhibitor. Additionally, it has anticholinergic effects.[3]
References
- ↑ Committee for Veterinary Medicinal Products: Denavering Hydrochloride Summary Report
- ↑ Dootz, H; Kuhlmann, A; Hoffmann, K (eds.). Rote Liste (in German) (2005 ed.). Aulendorf: Editio Cantor. 77 023. ISBN 3-87193-306-6.
- ↑ Dinnendahl, V; Fricke, U, eds. (2010). Arzneistoff-Profile (in German). 4 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
This article is issued from Wikipedia - version of the 6/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.